Efpeglenatide reduces the risk of major adverse CV events in patients with T2DM + established CVD or chronic kidney disease (AMPLITUDE-O)
There's more to see -- the rest of this topic is available only to subscribers.
© 2000–2024 Unbound Medicine, Inc. All rights reserved